HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,123,117 | +2.4% | 81,757 | -3.3% | 0.40% | +6.1% |
| Q2 2023 | $3,050,728 | -8.6% | 84,578 | -3.3% | 0.38% | -16.8% |
| Q1 2023 | $3,338,990 | -36.9% | 87,431 | -6.1% | 0.45% | -42.7% |
| Q4 2022 | $5,295,455 | +40.8% | 93,066 | -2.2% | 0.79% | +38.4% |
| Q3 2022 | $3,761,000 | -10.9% | 95,121 | -0.9% | 0.57% | -7.2% |
| Q2 2022 | $4,221,000 | +4.6% | 95,943 | -5.2% | 0.61% | +37.1% |
| Q1 2022 | $4,037,000 | -36.9% | 101,230 | -36.4% | 0.45% | -17.0% |
| Q4 2021 | $6,400,000 | -2.8% | 159,151 | -1.7% | 0.54% | -6.9% |
| Q3 2021 | $6,584,000 | -12.9% | 161,839 | -2.8% | 0.58% | -12.3% |
| Q2 2021 | $7,563,000 | +1.6% | 166,566 | -6.7% | 0.66% | -4.6% |
| Q1 2021 | $7,447,000 | -4.5% | 178,622 | -2.1% | 0.69% | +0.9% |
| Q4 2020 | $7,796,000 | +31.8% | 182,537 | -18.9% | 0.69% | +49.3% |
| Q3 2020 | $5,913,000 | – | 225,019 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |